← Back to Search

Pharmacological Agent

LTM1201AG for Obstructive Sleep Apnea

Phase 1 & 2

Recruiting

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

AHI > 10 events/h during NREM supine sleep

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 nights (treatment duration)

Awards & highlights

Study Summary

This trial is testing the effects of a new drug on sleep apnea patients.

Eligible Conditions

Obstructive Sleep Apnea

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 nights (treatment duration)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 nights (treatment duration)

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 nights (treatment duration) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Apnea hypopnea Index (AHI, average number of events for every hour of sleep)

Trial Design

5Treatment groups

Experimental Treatment

Placebo Group

Group I: LTM1201AZExperimental Treatment1 Intervention

LTM1201AZ capsule before bedtime

Group II: LTM1201ATExperimental Treatment1 Intervention

LTM1201AT capsule before bedtime

Group III: LTM1201AGExperimental Treatment1 Intervention

LTM1201AG capsule before bedtime

Group IV: LTM1201ADExperimental Treatment1 Intervention

LTM1201AD capsule before bedtime

Group V: PlaceboPlacebo Group1 Intervention

Placebo capsule before bedtime

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor

1,618 Previous Clinical Trials

11,471,694 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there current opportunities for individuals to join this experiment?

"The information posted on clinicaltrials.gov confirms that this research study is still actively recruiting candidates. The medical trial was first brought to light on March 1st 2019 and the details have recently been refreshed as of September 19th 2022."

Answered by AI

What is the upper limit of participants in this research study?

"Affirmative. According to clinicaltrials.gov, this research initiative which first began on March 1st 2019 is still accepting participants. The study requires 16 individuals who can travel to the single allocated site in order for it to reach completion."

Answered by AI

Is this research program open to elderly individuals?

"As per the inclusion criteria, eligible participants must be aged 18-70 years."

Answered by AI

Who is eligible to partake in this experiment?

"This sleep disorder trial is enrolling 16 individuals aged 18-70 with a minimum AHI of 10 events/h during NREM supine slumber. Obstructive Sleep apnea (OSA) must be diagnosed for admission."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pharmacological Activation of HMN for OSA Aim 2

Scott Aaron Sands 2019. "Pharmacological Activation of HMN for OSA Aim 2". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03858751.